Global Neurodegenerative Disease Market Insights Forecasts to 2033

• The Global Neurodegenerative Disease Market Size was Valued at USD 42.37 Billion in 2023
• The Market Size is Growing at a CAGR of 7.84% from 2023 to 2033
• The Worldwide Neurodegenerative Disease Market Size is Expected to Reach USD 90.10 Billion by 2033
• North America is Expected to Grow the fastest during the forecast period.

The Global Neurodegenerative Disease Market Size is Anticipated to Exceed USD 90.10 Billion by 2033, Growing at a CAGR of 7.84% from 2023 to 2033.

Market Overview

Neurodegenerative diseases are a group of disorders characterized by the progressive degeneration of nerve cells (neurons) in the brain and nervous system. Over time, this leads to a decline in cognitive functions, motor skills, and overall brain activity. Common neurodegenerative diseases include Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and Huntington's disease. These conditions are often chronic and worsen over time, with no known cures, although treatments may help manage symptoms or slow progression. The neurodegenerative disease market is expanding rapidly, driven by the increasing prevalence of these conditions due to aging populations and advances in medical research. Ongoing innovations, such as gene therapies, biologics, and disease-modifying treatments, are key drivers in this market.

Report Coverage

This research report categorizes the market for the global neurodegenerative disease market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global neurodegenerative disease market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global neurodegenerative disease market.

Driving Factors

Neurodegenerative diseases are influenced by aging, genetic predisposition, environmental influences, and lifestyle factors. Aging is the most significant risk factor, with diseases like Alzheimer's and Parkinson's increasing with age. Genetic mutations and family history are also significant. Environmental factors like toxins and head injuries increase the risk. Lifestyle choices like diet, inactivity, and stress can contribute to the onset or progression of these disorders.

Restraining Factors

Neurodegenerative diseases face challenges due to their complexity, high cost, and limited treatment efficacy. These disorders involve intricate biological processes, making early diagnosis difficult. The high cost of research, clinical trials, and regulatory approval also creates financial barriers. Current treatments focus on symptoms rather than disease progression.

Market Segmentation

The global neurodegenerative disease market share is classified into disease, route of administration, and drug

• The Alzheimer's disease segment is expected to hold the largest share of the global neurodegenerative disease market during the forecast period.   

Based on the disease, the global neurodegenerative disease market is divided into Alzheimer's disease, Parkinson's disease, Huntington's disease, and multiple sclerosis. Among these, the Alzheimer's disease segment is expected to hold the largest share of the global neurodegenerative disease market during the forecast period. The segment will experience the most significant growth in the neurodegenerative disease market due to the aging global population and increasing investment in research and development for treatments. The increasing awareness of Alzheimer's and the growing healthcare burden associated with dementia are driving demand for more effective treatments, contributing to the expected market growth.

• The injectable segment is expected to grow at the fastest CAGR in the global neurodegenerative disease market during the forecast period.   

Based on the route of administration, the global neurodegenerative disease market is divided into oral, injectable, transdermal, and others. Among these, the injectable segment is expected to grow at the fastest CAGR in the global neurodegenerative disease market during the forecast period. The segment is expected to grow significantly in the neurodegenerative disease market due to the increasing adoption of biologics, gene therapies, and monoclonal antibodies. These injectable treatments offer higher bioavailability and targeted delivery, making them effective for managing neurodegenerative conditions. The development of long-acting injectables is also fueling growth.

• The gene therapy segment is expected to grow at the fastest CAGR in the global neurodegenerative disease market during the forecast period.   

Based on the drug, the global neurodegenerative disease market is divided into cholinesterase inhibitors, gene therapy, NMDA receptor antagonists, and dopaminergic drugs. Among these, the gene therapy segment is expected to grow at the fastest CAGR in the global neurodegenerative disease market during the forecast period. The segment is expected to experience significant growth due to advances in genetic research and the focus on addressing underlying causes. It targets genetic mutations and faulty proteins contributing to conditions like Huntington's disease, amyotrophic lateral sclerosis (ALS), and Parkinson's. With promising clinical trials and regulatory approvals, this segment is poised for rapid expansion.

Regional Segment Analysis of the Global Neurodegenerative Disease Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

Asia Pacific is anticipated to hold the largest share of the global neurodegenerative disease market over the predicted timeframe.

Asia Pacific is anticipated to hold the largest share of the global neurodegenerative disease market over the predicted timeframe. The region is expected to dominate the global neurodegenerative disease market due to aging populations, increasing prevalence of disorders, and growing healthcare infrastructure. Countries like China and India are experiencing increased incidences of Alzheimer's and Parkinson's, requiring innovative treatments. The region's research, awareness, and government support also contribute to its growth.

North America is expected to grow at the fastest pace in the global neurodegenerative disease market during the forecast period. The region is dominated by the US, Canada, and Mexico, and is bolstered by a robust healthcare system, advanced research, and significant investments in pharmaceuticals and biotechnology. The aging population and increased awareness of neurodegenerative disorders drive demand for innovative therapies. However, challenges like high treatment costs and healthcare access could limit market growth.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global neurodegenerative disease market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Biogen Inc.
• Eli Lilly and Company
• Roche Holding AG
• Novartis AG
• Pfizer Inc.
• AstraZeneca plc
• Bristol-Myers Squibb
• Merck & Co., Inc.
• AbbVie Inc.
• Amgen Inc.
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• Neurocrine Biosciences, Inc.
• Otsuka Pharmaceutical Co., Ltd.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In July 2024, Alpha Cognition, a biopharmaceutical company received FDA approval for ZUNVEYL, a benzgalantamine, for treating mild-to-moderate Alzheimer's disease.

• In May 2024, NeuroSense Therapeutics partnered with PhaseV, a leading machine learning company, for the Phase 3 trial of PrimeC, a treatment for ALS.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global neurodegenerative disease market based on the below-mentioned segments:

Global Neurodegenerative Disease Market, By Disease

• Alzheimer's Disease
• Parkinson's Disease
• Huntington's Disease
• Multiple Sclerosis

Global Neurodegenerative Disease Market, By Route of Administration

• Oral
• Injectable
• Transdermal
• Others

Global Neurodegenerative Disease Market, By Drug

• Cholinesterase Inhibitors
• Gene Therapy
• NMDA Receptor Antagonists
• Dopaminergic Drugs

Global Neurodegenerative Disease Market, Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa